New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National ...

Trastuzumab deruxtecan is a targeted drug used to treat certain types of cancer: breast cancer, gastric or gastroesophageal ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for ...

The Food and Drug Administration (FDA) has expanded the list of medicines exempted from value-added tax (VAT) to ensure ...

Product review details, this product has received, on average, 4.70 out of 5 star rating.

Adding albumin to PN solutions can affect infusion flow rates and pump pressures, thereby compromising the appropriate delivery of PN solutions to patients. The theoretical risk of glycosylation ...

2-Year U.S. Treasury Note Continuous Contract $103.063-0.023-0.02% 5-Year U.S. Treasury Note Continuous Contract $107.445-0.070-0.07% 10-Year U.S. Treasury Note Continuous Contract $110.875-0.125 ...

The Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval of additional indication of US-based Bristol-Myers Squibb's anti-cancer drug ...

pharmacokinetic profile supporting a 24-hour infusion, (3) stable PN solution infusion rate, (4) documented physical stability over at least 24 hours, and (5) documented chemical stability over at ...